Table 1.
Demographic and TPE characteristics.
| Characteristics | N (%) |
|---|---|
| Age∗∗ | 50 (32–64) |
|
| |
| Sex | |
| Female | 104 (55.6) |
| Male | 83 (44.4) |
|
| |
| Autoimmune neurological disease | 187 (100) |
| MG | 70 (37.4) |
| GBS | 53 (28.3) |
| NMOSD | 35 (18.7) |
| CIDP | 23 (12.3) |
| AE | 6 (3.2) |
|
| |
| Types of replacement solutions | |
| Albumin | 131 |
| Succinylated gelatin | 45 |
| Albumin + succinylated gelatin | 10 |
| Albumin + fresh frozen plasma | 1 |
| Number of TPEs by patient ∗∗ | 5 (5–5) |
∗∗Median (IQR). MG, myasthenia gravis; GBS, Guillain–Barré syndrome; NMOSD, neuromyelitis optica spectrum disorders; CIDP, chronic inflammatory demyelinating polyneuropathy; AE, autoimmune encephalitis. TPE, therapeutic plasmatic exchange.